83 / 916
25th European Congress of Psychiatry / European Psychiatry 41S (2017) S69–S105
S79
ous public health problem and a major challenge to treatment
providers.
Disclosure of interest
The authors have not supplied their decla-
ration of competing interest.
http://dx.doi.org/10.1016/j.eurpsy.2017.01.250O029
Clinical outcomes of the first 2 years
of implementation of the integrated
care pathway for concurrent major
depressive disorder and alcohol use
disorder
A.V. Samokhvalov
1 ,∗
, S. Awan
2, B. Le Foll
3, C. Probst
4, P. Voore
5,
J. Rehm
41
Centre for Addiction and Mental Health, Institute for Mental Health
Policy Research/Addiction Medicine Service, Toronto, Canada
2
Centre for Addiction and Mental Health, Integrated Care Pathways
Program, Toronto, Canada
3
Centre for Addiction and Mental Health, Addiction Medicine Service,
Toronto, Canada
4
Centre for Addiction and Mental Health, Institute for Mental Health
Policy Research, Toronto, Canada
5
Centre for Addiction and Mental Health, Ambulatory Care and
Structured Treatments, Toronto, Canada
∗
Corresponding author.
Background
Both major depressive disorder (MDD) and alcohol
use disorder are highly prevalent, often comorbid and cause sig-
nificant socioeconomic burden. At CAMH, we have developed and
integrated care pathway (ICP) to treat these disorders and evalu-
ated its effectiveness in comparison to treatment as usual (TAU)
Methods
Chart review; descriptive statistics, c
2
and
t
-tests, linear
mixed effects models, Kaplan–Meier and log-rank analyses.
Results
Overall, 81 patients were enrolled into ICP. Comparisons
of treatment retention rates between ICP patients andmatched his-
torical controls (
n
= 81) showed significantly lower dropout rate
in ICP cohort (18.5% vs. 69.1%,
P
< 0.001,
Fig. 1 ).The ICP patients
demonstrated significant reduction in depressive symptoms sever-
ity (QIDS: 14.6 vs. 10.0,
P
< 0.001; BDI 26.3 vs. 16.2,
P
< 0.001),
reduction in the amount of alcohol consumed weekly from 44.6
standard drinks at baseline to 12.6 (
P
< 0.001) by the end of treat-
ment, which was significantly better compared to controls (56.9 vs.
25.2,
P
< 0.001),
P
= 0.014
( Fig. 2 ).Conclusions
The ICP is a feasible approach to treatment of con-
current AUD and MDD with significantly higher retention rates
than TAU. Patients demonstrate improvements on several levels
including depressive symptoms, and changes in alcohol drinking
patterns.
Fig. 1
Fig. 2
Disclosure of interest
The authors have not supplied their decla-
ration of competing interest.
http://dx.doi.org/10.1016/j.eurpsy.2017.01.251O030
Party hard: Drug-related fatalities in
Ibiza from 2010 to 2016
R. Santacroce
1 ,∗
, C. Ruiz Bennasar
2, J.R. Sancho Jaraiz
2,
C. Montemitro
1, G. Baroni
1, M. Corbo
1, A. Pasquini
1,
F. Sarchione
1, F. Angelini
1, G. Catalano
3, M.L. Carenti
3,
C. Di Taranto
4, S. Tenuta
4, U. Lecciso
4, M. De Angelis
4,
A. Rondoni
4 , M.Di Giannantonio
1 , G.Martinotti
11
University “G.d’Annunzio”, Department of Neuroscience- Imaging
and Clinical Sciences, Chieti, Italy
2
Instituto de Medicina Legal de Las Illes Balears, Subdirección de
Ibiza, Ibiza, Spain
3
Libera Università Maria SS Assunta, Dipartimento di Scienze
Umane, Rome, Italy
4
Casa di Cura Villa Maria Pia, Servizio di Neuropsichiatria, Rome,
Italy
∗
Corresponding author.
Introduction
Illicit drug use is well known as an important con-
tributor to the global burden of diseases, but the physical and
psychopathological risks of recreational drugs misuse are often
underestimated and drug-related fatalities in specific settings are
under-investigated.